Lu, Yuting published the artcileImpurity profiling of varenicline tartrate by LC-QTOF mass spectrometric techniques during drug development, Product Details of C17H19N3O6, the publication is Journal of Pharmaceutical and Biomedical Analysis (2018), 306-313, database is CAplus and MEDLINE.
HPLC-QTOF-MS method was developed for the separation and characterization of related substances in varenicline tartrate drug material. The separation used InertSustain C18 column (4.6 × 150 mm, 5 μm) with liner gradient elution using 0.05% trifluoroacetic acid as mobile phase A and acetonitrile as mobile phase B. The degradation studies were conducted under the ICH prescribed stress conditions. Varenicline tartrate was unstable to alk., oxidative, thermal and photolytic stresses, but relatively stable under acid stress condition. Thirteen related substances were found in varenicline tartrate and its stressed samples. Their structures were identified mainly through pos. ESI high resolution QTOF mass spectrometric anal. of the parent and product ion accurate masses and the calculated elemental compositions Among the 13 substances, 7 were process-related and 6 were degradation products, and two of them were further verified by chem. synthesis and NMR spectroscopic determination Their formation mechanisms are discussed, and the key steps in the manufacturing processes are determined to provide varenicline tartrate with high purity.
Journal of Pharmaceutical and Biomedical Analysis published new progress about 375815-87-5. 375815-87-5 belongs to quinoxaline, auxiliary class Neuronal Signaling,AChR,Natural product, name is 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate, and the molecular formula is C17H19N3O6, Product Details of C17H19N3O6.
Referemce:
https://en.wikipedia.org/wiki/Quinoxaline,
Quinoxaline | C8H6N2 | ChemSpider